Overview of angiogenesis: Biologic implications for antiangiogenic Therapy

Seminars in Oncology

Volumn 28, Issue 5 SUPPL. 16, 2001, Pages 94-104

  Ellis, Lee M ^a   Liu, Wenbiao ^a   Ahmad, Syed A ^a   Fan, Fan ^a   Jung, Young Do ^a   Shaheen, Raymond M ^a   Reinmuth, Niels ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; THROMBOSPONDIN; THROMBOSPONDIN DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VINCRISTINE;

ACIDITY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CELL SURVIVAL; CELL TYPE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DRUG EFFICACY; HEMANGIOMA; HUMAN; HYPOXIA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TOXICITY; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION;

EID: 0035173755     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.28560     Document Type: Conference Paper

References (70)

1. What is the evidence that tumors are angiogenesis dependent?
2. The implications of angiogenesis for the biology and therapy of cancer metastasis
3. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma
4. Tumor angiogenesis: Review of current applications in tumor prognostication
5. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis
6. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer
7. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer
8. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract
9. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas
10. Quantitative analysis of vascular endothelial growth factor in primary breast cancer
11. The human gene for vascular endothelial growth factor: Multiple protein forms are encoded through alternate exon splicing
12. Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs: Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression
13. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
14. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation
15. KDR receptor: A key marker defining hematopoietic stem cells
16. Expression of vascular endothelial growth factor receptors in human prostate cancer
17. Tumor angiogenesis is regulated by CXC chemokines
18. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
19. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
20. Integrins: Versatility, modulation, and signaling in cell adhesion
21. The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
22. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis
23. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival
24. Control of angiogenesis by the pericyte: Molecular mechanisms and significance
25. PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate
26. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice
27. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse
28. Direct actions of angiopoietin-1 on human endothelium: Evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors
29. Is angiopoietin-2 necessary for the initiation of tumor angiogenesis?
30. The angiopoietins: Yin and Yang in angiogenesis
31. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
32. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia
33. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis
34. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
35. Hypoxic induction of human vascular endothelial growth factor expression through c-src activation
36. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src
37. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I
38. Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1 beta
39. Vascular endothelial growth factor in human glioma cell lines: Induced secretion by EGF, PDGF-BB, and bFGF
40. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer
41. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element
42. Hypoxiainducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
43. Extracellular signalregulated kinase activation is required for upregulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells
44. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
45. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways
46. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity
47. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein
48. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer
49. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
50. Synergy between an antiangiogenic integrin alphav antagonist and an antibodycytokine fusion protein eradicates spontaneous tumor metastases
51. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
52. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
53. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
54. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma
55. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen
56. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer
57. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice
58. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
59. The generation of endostatin is mediated by elastase
60. Endostatin induces endothelial cell apoptosis
61. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth
62. Mouse endostatin inhibits the formation of lung and liver metastases
63. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy
64. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a
65. Interferon alpha in the treatment of AIDS-related Kaposi's sarcoma
66. Treatment of hemangioendotheliomas with alpha interferon
67. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas
68. Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway
69. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
70. Continuous lowdose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity